Case Report: Hemophagocytic lymphohistiocytosis masquerading as drug-induced liver injury: successful treatment with low-dose ruxolitinib and glucocorticoids - Scorecard - MDSpire
Advertisement
Case Report: Hemophagocytic lymphohistiocytosis masquerading as drug-induced liver injury: successful treatment with low-dose ruxolitinib and glucocorticoids
Clinical Scorecard: Clinical Case Study: Hemophagocytic Lymphohistiocytosis Presenting as Drug-Induced Liver Injury Treated Effectively with Low-Dose Ruxolitinib and Corticosteroids
At a Glance
Category
Detail
Condition
Hemophagocytic lymphohistiocytosis (HLH)
Key Mechanisms
Uncontrolled activation of macrophages and cytotoxic T cells leading to excessive cytokine release and multiorgan dysfunction.
Target Population
Adults presenting with drug-induced liver injury (DILI) and secondary HLH.
Care Setting
Infectious disease department of a hospital.
Key Highlights
HLH can present as severe DILI, complicating diagnosis.
Low-dose ruxolitinib combined with corticosteroids showed rapid clinical response.
All patients exhibited severe hyperbilirubinemia and cytopenias.
Genetic testing revealed variants in immune-regulatory genes.
No significant adverse events related to ruxolitinib were observed.
Guideline-Based Recommendations
Diagnosis
Consider HLH in patients with severe DILI and hyperinflammatory symptoms.
Management
Administer low-dose ruxolitinib combined with corticosteroids for treatment.
Monitoring & Follow-up
Monitor bilirubin and inflammatory markers for treatment response.
Risks
Potential for transient declines in blood counts.
Patient & Prescribing Data
Three adult patients with DILI-like hepatic injury and secondary HLH.
Combination therapy resulted in progressive normalization of bilirubin and inflammatory markers.
Clinical Best Practices
Early recognition of HLH in patients with predominant hepatic manifestations.
Timely immunomodulatory therapy may improve outcomes.
